Hematologic Malignancies Clinical Trials in Zhengzhou, Henan
6 recruitingZhengzhou, Henan, China
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.71 enrolled16 locationsNCT06756451
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 1
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
Advanced Hematologic Malignancies
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.114 enrolled3 locationsNCT07113925